The Cochlear Limited (ASX: COH) share price is down after investors heard about the coronavirus earnings downgrade.
What is the downgraded guidance?
The hearing device business had previously been guiding that FY20 underlying net profit would be in the range of $290 million to $300 million, which would have been an increase of 9% to 13%.
However, the impact of the novel coronavirus in Greater China has caused Cochlear to reduce its guidance to $270 million to $290 million, which would be an increase of 2% to 9%. This guidance assumes only Greater China sales are impacted.
What has happened to Cochlear in China?
Hospitals across Greater China, which includes Hong Kong and Taiwan, are currently deferring surgeries, including cochlear implants, to limit the risk of infection from the coronavirus.
During the SARS epidemic, Cochlear also experienced a fall in sales in China over a three-month period but then saw a rise in activity as the delayed surgeries were carried out. Cochlear thinks the delayed surgeries this year will progress once normal operations resume.
Cochlear CEO and President Dig Howitt said: “It has become clear that the coronavirus will impact a number of cochlear implant surgeries in Greater China, a top 5 market for Cochlear. Limiting the risk of exposure to the virus is an appropriate precaution. While we cannot predict how long surgeries will be delayed, the low end of guidance factors in a significant decline in sales for Greater China for the second half.”
Cochlear’s supply chain
Cochlear’s guidance also assumes there will not be any material disruption to its supply chain, including importing components from China.
The company is expecting Chinese suppliers to return to normal production of components soon, which are primarily for sound processors and accessories. Cochlear has at least three months of inventory of most components and “at this stage do not expect any disruption to our ability to supply products to our customers”.
Final Cochlear Comments
Cochlear said it remains committed to increasing its presence in China. Mr Howitt said: “Cochlear continues to invest in expanding its market presence and developing a manufacturing footprint in China as we believe in the long-term potential of the market. The Chinese cochlear implant market is important now and into the future and we remain committed to maintaining a leading position.”
The Cochlear share price was down 3% just after the market opened.
The post Cochlear share price down on coronavirus downgrade appeared first on Motley Fool Australia.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares to buy now
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2020
- 5 Stocks for Potentially Building Wealth After 50
Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020